BRAF and non-small cell lung carcinoma: Similarly, BRAF inhibitors result in initial dramatic responses in BRAF mutant melanoma and NSCLC, however these tumors also progress on therapy through additional acquired genetic alterations in BRAF and other factors resulting in pathway reactivation [6].